FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2395239607> ?p ?o ?g. }

• W2395239607 endingPage "138" @default.
• W2395239607 startingPage "128" @default.
• W2395239607 abstract "AimTo evaluate (I) trastuzumab-containing primary systemic therapy (PST) in human epidermal growth factor receptor 2 (Her2) overexpressing breast carcinomas; (II) compare the patients who achieved and those who did not achieve pathological complete remission (pCR), and (III) analyze the accuracy of different clinical-imaging modalities in tumor response monitoring.Methods188 patients who received PST between 2008 and 2014 were reviewed and 43 Her2 overexpressing breast cancer patients (28 Luminal B/Her2-positive and 15 Her2-positive) were enrolled. 26 patients received mostly taxane-based PST without trastuzumab (Group 1) and 17 patients received trastuzumab-containing PST (Group 2). We compared the concordance between pCR and complete remission (CR) defined by breast-ultrasound, CR defined by standard 18F-fluoro-deoxy-glucose positron emission tomography and computerized tomography (FDG-PET/CT) criteria (Method 1) and CR defined by a novel, breast cancer specific FDG-PET/CT criteria (Method 2). Sensitivity (sens), specificity (spec), and positive (PPV) and negative predictive values (NPV) were calculated.Results10 patients (38.5%) in Group 1 and 8 (47%) in Group 2 achieved pCR. pCR was significantly more frequent in Her2-positive than in Luminal B/Her2-positive tumors in both Group 1 (P = 0.043) and Group 2 (P = 0.029). PET/CT evaluated by the breast cancer specific criteria (PET/CT Method 2) differentiated pCR from non-pCR more accurately in both groups (Group 1: sens = 77.8%, spec = 100%, PPV = 100%, NPV = 71.4%; Group 2: sens = 87.5%, spec = 62.5%, PPV = 70%, NPV = 83.3%) than standard PET/CT criteria (Method 1) (Group 1: sens = 22.2% spec = 100% PPV = 100% NPV = 41.7%; in Group 2: sens = 37.5%, spec = 87.5%, PPV = 75% NPV = 58.3%) or breast ultrasound (Group 1, sens = 83.3% spec = 25% PPV = 62.5% NPV = 50%; Group 2, sens = 100% spec = 12.5% PPV = 41.6% NPV = 100%).ConclusionThe benefit of targeted treatment with trastuzumab-containing PST in Her2 overexpressing breast cancer was defined in terms of pCR rate. Luminal B/Her2-positive subtype needs further subdivision to identify patients who would benefit from PST. Combined evaluation of tumor response by our novel, breast cancer specific FDG-PET/CT criteria accurately differentiated pCR from non-pCR patients." @default.
• W2395239607 created "2016-06-24" @default.
• W2395239607 creator A5000223829 @default.
• W2395239607 creator A5001393770 @default.
• W2395239607 creator A5015401716 @default.
• W2395239607 creator A5025663866 @default.
• W2395239607 creator A5031714311 @default.
• W2395239607 creator A5039788677 @default.
• W2395239607 creator A5042827731 @default.
• W2395239607 creator A5065916969 @default.
• W2395239607 creator A5087779487 @default.
• W2395239607 creator A5055376251 @default.
• W2395239607 date "2015-04-01" @default.
• W2395239607 modified "2023-10-17" @default.
• W2395239607 title "Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study" @default.
• W2395239607 cites W1955397179 @default.
• W2395239607 cites W1963755646 @default.
• W2395239607 cites W1985213644 @default.
• W2395239607 cites W1987326983 @default.
• W2395239607 cites W1989118158 @default.
• W2395239607 cites W1991715141 @default.
• W2395239607 cites W1992234802 @default.
• W2395239607 cites W1994150148 @default.
• W2395239607 cites W1995308403 @default.
• W2395239607 cites W1999547551 @default.
• W2395239607 cites W2005124079 @default.
• W2395239607 cites W2015884933 @default.
• W2395239607 cites W2018871196 @default.
• W2395239607 cites W2019607817 @default.
• W2395239607 cites W2024338885 @default.
• W2395239607 cites W2025883350 @default.
• W2395239607 cites W2027448381 @default.
• W2395239607 cites W2038851440 @default.
• W2395239607 cites W2039465932 @default.
• W2395239607 cites W2052295501 @default.
• W2395239607 cites W2058085109 @default.
• W2395239607 cites W2071014537 @default.
• W2395239607 cites W2078344611 @default.
• W2395239607 cites W2088325440 @default.
• W2395239607 cites W2095865154 @default.
• W2395239607 cites W2096149428 @default.
• W2395239607 cites W2097313333 @default.
• W2395239607 cites W2097833110 @default.
• W2395239607 cites W2101979288 @default.
• W2395239607 cites W2104337757 @default.
• W2395239607 cites W2104597416 @default.
• W2395239607 cites W2108863890 @default.
• W2395239607 cites W2112160480 @default.
• W2395239607 cites W2113242459 @default.
• W2395239607 cites W2117775530 @default.
• W2395239607 cites W2117984780 @default.
• W2395239607 cites W2123591186 @default.
• W2395239607 cites W2130900820 @default.
• W2395239607 cites W2131915049 @default.
• W2395239607 cites W2135198751 @default.
• W2395239607 cites W2143967388 @default.
• W2395239607 cites W2145938281 @default.
• W2395239607 cites W2146499691 @default.
• W2395239607 cites W2147415463 @default.
• W2395239607 cites W2155263737 @default.
• W2395239607 cites W2158248853 @default.
• W2395239607 cites W2164774797 @default.
• W2395239607 cites W2169149961 @default.
• W2395239607 cites W2171958606 @default.
• W2395239607 cites W2231925625 @default.
• W2395239607 cites W2597872842 @default.
• W2395239607 cites W201011106 @default.
• W2395239607 doi "https://doi.org/10.3325/cmj.2015.56.128" @default.
• W2395239607 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4410165" @default.
• W2395239607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25891872" @default.
• W2395239607 hasPublicationYear "2015" @default.
• W2395239607 type Work @default.
• W2395239607 sameAs 2395239607 @default.
• W2395239607 citedByCount "4" @default.
• W2395239607 countsByYear W23952396072016 @default.
• W2395239607 countsByYear W23952396072020 @default.
• W2395239607 countsByYear W23952396072023 @default.
• W2395239607 crossrefType "journal-article" @default.
• W2395239607 hasAuthorship W2395239607A5000223829 @default.
• W2395239607 hasAuthorship W2395239607A5001393770 @default.
• W2395239607 hasAuthorship W2395239607A5015401716 @default.
• W2395239607 hasAuthorship W2395239607A5025663866 @default.
• W2395239607 hasAuthorship W2395239607A5031714311 @default.
• W2395239607 hasAuthorship W2395239607A5039788677 @default.
• W2395239607 hasAuthorship W2395239607A5042827731 @default.
• W2395239607 hasAuthorship W2395239607A5055376251 @default.
• W2395239607 hasAuthorship W2395239607A5065916969 @default.
• W2395239607 hasAuthorship W2395239607A5087779487 @default.
• W2395239607 hasBestOaLocation W23952396071 @default.
• W2395239607 hasConcept C121608353 @default.
• W2395239607 hasConcept C126322002 @default.
• W2395239607 hasConcept C143998085 @default.
• W2395239607 hasConcept C160798450 @default.
• W2395239607 hasConcept C2775842073 @default.
• W2395239607 hasConcept C2777511904 @default.
• W2395239607 hasConcept C2779786085 @default.
• W2395239607 hasConcept C2989005 @default.
• W2395239607 hasConcept C530470458 @default.

• next